Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Eiger BioPharmaceuticals, Inc. (EIGR)

4.14   -0.39 (-8.61%) 12-05 16:00
Open: 4.52 Pre. Close: 4.53
High: 4.52 Low: 3.93
Volume: 523,876 Market Cap: 182(M)

Technical analysis

as of: 2022-12-06 8:17:39 AM
Overall:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 5.72     One year: 6.43
Support: Support1: 3.92    Support2: 3.26
Resistance: Resistance1: 4.9    Resistance2: 5.51
Pivot: 4.28
Moving Average: MA(5): 4.4     MA(20): 4.26
MA(100): 6.78     MA(250): 6.35
MACD: MACD(12,26): -0.3     Signal(9): -0.4
Stochastic oscillator: %K(14,3): 61.4     %D(3): 70.1
RSI: RSI(14): 39.1
52-week: High: 10.02  Low: 3.52
Average Vol(K): 3-Month: 340 (K)  10-Days: 285 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ EIGR ] has closed above bottom band by 31.4%. Bollinger Bands are 59.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.53 - 4.55 4.55 - 4.57
Low: 3.87 - 3.9 3.9 - 3.92
Close: 4.1 - 4.14 4.14 - 4.18

Company Description

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.

Headline News

Tue, 06 Dec 2022
EIGR ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of January 9, 2023 in the Class Action Filed on Behalf of Eiger BioPharmaceuticals, Inc. Shareholders - PR Newswire

Mon, 05 Dec 2022
CLASS ACTION UPDATE for SQ, CMP and EIGR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Beh - Benzinga

Mon, 05 Dec 2022
Positive week for Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) institutional investors who lost 23% over the past year - Simply Wall St

Fri, 02 Dec 2022
EIGR LAWSUIT ALERT: Levi & Korsinsky Notifies Eiger BioPharmaceuticals, Inc. Investors of a Class Action - Benzinga

Wed, 30 Nov 2022
DEADLINE ALERT for FIGS, EVA, EIGR, TSP: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders - GlobeNewswire

Mon, 28 Nov 2022
Eiger Biopharmaceuticals, Inc. (EIGR) Equity Notice: Contact Robbins LLP if You Incurred Significant Damages From Your Investment in Eiger Biopharmaceuticals, Inc. - GlobeNewswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 44 (M)
Shares Float 37 (M)
% Held by Insiders 5.2 (%)
% Held by Institutions 70.6 (%)
Shares Short 1,820 (K)
Shares Short P.Month 1,930 (K)

Stock Financials

EPS -2.51
EPS Est Next Qtl -1.31
EPS Est This Year -5.2
EPS Est Next Year -4.87
Book Value (p.s.) 1.77
Profit Margin (%) 0
Operating Margin (%) -630.4
Return on Assets (ttm) -39.3
Return on Equity (ttm) -111.4
Qtrly Rev. Growth 32.4
Gross Profit (p.s.) 0.25
Sales Per Share 0.32
EBITDA (p.s.) -2.02
Qtrly Earnings Growth 0
Operating Cash Flow -78 (M)
Levered Free Cash Flow -44 (M)

Stock Valuations

PE Ratio -1.66
PEG Ratio 0
Price to Book value 2.32
Price to Sales 12.89
Price to Cash Flow -2.36

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.